MLTX | MRK | MRK:CA | NVS | NVS:CA | NVSEF | Terry Chrisomalis MoonLake Immunotherapeutics: More Sonelokimab Success, With Big Pharma Interest ByMario Cazombo June 3, 2025
KYMR | REGN | SNY | SNYNF | Terry Chrisomalis Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data ByMario Cazombo June 2, 2025
SMMT | Terry Chrisomalis Summit Therapeutics: Moving Stock To ‘Hold’ Rating After Phase 3 HARMONi Data Release ByMario Cazombo May 30, 2025
Terry Chrisomalis | TSHA Taysha: TSHA-102 Presses On With IND Part B Protocol And SAP Amendments ByMario Cazombo May 29, 2025
RCKT | RCKTW | Terry Chrisomalis Rocket Pharmaceuticals: Despite FDA Clinical Hold On RP-A501, Prospects Remain Intact ByMario Cazombo May 28, 2025
BMY | BMYMP | CELG.RT | JNJ | JNJ:CA | NONOF | NVO | NVON:CA | PRTA | RHHBF | RHHBY | RHHVF | ROCH:CA | ROG:CA | Terry Chrisomalis Prothena: Despite Phase 3 Trial Failure, Other Neurodegenerative Programs In Place ByMario Cazombo May 27, 2025
